Trial in CD30-Positive Malignancies

Study ID: SGN35-013

This trial is currently enrolling patients in the following locations:


  • Birmingham


  • Duarte
  • Oxnard


  • Denver


  • Jacksonville
  • Ocala


  • Indianapolis


  • Boston


  • Minneapolis

New York

  • Albany


  • Cleveland


  • Eugene
  • Tualatin

South Carolina

  • Greenville


  • Bedford
  • Dallas
  • Denton
  • Fort Worth
  • Houston
  • Round Rock
  • San Antonio
  • Waco


  • Christianburg
  • Fairfax


  • Edmonds
  • Spokane Valley
  • Yakima

For further information, please call: 866-333-7436 or email Your message will be returned by the next business day.

Updated April 2, 2014

Study Name

A phase 2 study of brentuximab vedotin in patients with CD30-positive malignancies other than lymphoma (this includes acute lymphoid leukemia, acute myeloid leukemia, multiple myeloma, and a number of solid tumors).

What is a phase 2 study?

A phase 2 study is normally a study that is done to see not only if the drug is safe in people, but whether it might be efficacious in treating a specific disease.

Who can participate?

  • You are 6 years or older.
  • Your malignancy is non-lymphoma and is tested and determined to be CD30-positive.
  • You have failed, refused, or have been are ineligible for standard therapy.
  • At a minimum, you are ambulatory and able to carry out light work.
  • Lab tests meet a minimum requirement.
  • Other criteria apply. You will need to see a study doctor to determine if you are able to participate.

Why is the study being done?

This study is being done to gather information about the effectiveness of a drug called brentuximab vedotin when given alone to patients whose non-lymphoma cancers test positive for the CD30 antigen.

You are now leaving Seattle Genetics' site. Seattle Genetics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave

No, return to

Yes, leave